Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Exagen (XGN) Change in Receivables (2018 - 2025)

Exagen (XGN) has disclosed Change in Receivables for 8 consecutive years, with -$237000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Receivables rose 84.73% year-over-year to -$237000.0, compared with a TTM value of $3.0 million through Dec 2025, up 135.2%, and an annual FY2025 reading of $3.0 million, up 135.2% over the prior year.
  • Change in Receivables was -$237000.0 for Q4 2025 at Exagen, up from -$3.6 million in the prior quarter.
  • Across five years, Change in Receivables topped out at $6.9 million in Q2 2023 and bottomed at -$10.5 million in Q4 2023.
  • Average Change in Receivables over 5 years is $97250.0, with a median of $437000.0 recorded in 2021.
  • The sharpest move saw Change in Receivables crashed 1127.48% in 2022, then surged 415.66% in 2023.
  • Year by year, Change in Receivables stood at $444000.0 in 2021, then plummeted by 1127.48% to -$4.6 million in 2022, then tumbled by 130.01% to -$10.5 million in 2023, then skyrocketed by 85.21% to -$1.6 million in 2024, then skyrocketed by 84.73% to -$237000.0 in 2025.
  • Business Quant data shows Change in Receivables for XGN at -$237000.0 in Q4 2025, -$3.6 million in Q3 2025, and -$1000.0 in Q2 2025.